Trohatou Ourania, Roubelakis Maria G
1 Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens , Athens, Greece .
2 Cell and Gene Therapy Laboratory, Centre of Basic Research II , Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece .
Cell Reprogram. 2017 Aug;19(4):217-224. doi: 10.1089/cell.2016.0062. Epub 2017 May 18.
The concept of Regenerative Medicine combined with Cell based Therapy and Tissue Engineering represents the fourth pillar of healthcare and provides a promising approach for the treatment of serious diseases. Recently, cell based therapies are focused on the use of mesenchymal stem/stromal cells (MSCs). Human MSCs, that represent a mesoderm derived population of progenitors, are easily expanded in culture. They are capable to differentiate into osteoblasts, chondrocytes, and adipocytes and exhibit the potential to repair or regenerate damaged tissues. The best characterized source of human MSCs to date is the bone marrow; recently, fetal sources, such as amniotic fluid, umbilical cord, amniotic membranes, or placenta, have also attracted increased attention. Thus, MSCs may represent a valuable tool for tissue repair and cell therapeutic applications. To this end, the main focus of this review is to summarize and evaluate the key characteristics, the sources, and the potential use of MSCs in therapeutic approaches and modalities.
再生医学与基于细胞的治疗和组织工程相结合的概念代表了医疗保健的第四大支柱，并为严重疾病的治疗提供了一种有前景的方法。最近，基于细胞的治疗主要集中在间充质干/基质细胞（MSCs）的使用上。人MSCs是一群中胚层来源的祖细胞，易于在培养中扩增。它们能够分化为成骨细胞、软骨细胞和脂肪细胞，并具有修复或再生受损组织的潜力。迄今为止，人MSCs最具特征的来源是骨髓；最近，胎儿来源，如羊水、脐带、羊膜或胎盘，也引起了越来越多的关注。因此，MSCs可能是组织修复和细胞治疗应用的一种有价值的工具。为此，本综述的主要重点是总结和评估MSCs在治疗方法和模式中的关键特征、来源及潜在用途。
